Difference between revisions of "Prostate cancer, BRCA-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable sortable" style="width: 75%; text-align:center;"" to "{| class="wikitable sortable" style="width: 60%; text-align:center;"") |
|||
| Line 25: | Line 25: | ||
|} | |} | ||
===Regimen {{#subobject:68aa39|Variant=1}}=== | ===Regimen {{#subobject:68aa39|Variant=1}}=== | ||
| − | {| class="wikitable sortable" style="width: | + | {| class="wikitable sortable" style="width: 60%; text-align:center;" |
!style="width: 33%"|Study | !style="width: 33%"|Study | ||
!style="width: 33%"|Years of enrollment | !style="width: 33%"|Years of enrollment | ||
Revision as of 01:01, 1 July 2021
| Page editor | Section editor | ||
|---|---|---|---|
 |
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA  LauraGrahamMD
|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki
|
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Rucaparib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| (TRITON2) | 2017-NR | Phase II (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534